Clinical Topics

Patients Treated with Thiopurines Have Higher Skin Cancer Mortality

by U.S. Medicine

July 22, 2019

PHILADELPHIA—Treatment with thiopurines is associated with an increased risk of squamous cell carcinoma of the skin in patients with inflammatory bowel diseases.

An article in Clinical Gastroenterology and Hepatology discussed results of a study that looked at outcomes of patients with IBD who developed SCC while receiving thiopurine therapy.1

Researchers from Corporal Michel J. Crescenz VAMs and the Perelman School of Medicine at the University of Pennsylvania conducted a retrospective cohort study of 54,919 patients with IBD followed in the nationwide VA health system from Jan. 1, 2000, through May 23, 2018.

A subcohort was created of patients with an incident diagnosis of SCC, confirmed by review of patients’ medical records. The study team looked at those who had received treatment with thiopurines (exposed group) vs. those treated with mesalamine and no prior exposure to thiopurines or tumor necrosis factor antagonists (unexposed group). Identifying 467 patients with incident SCC, researchers included 449 patients (161 exposed and 288 unexposed) in their final analysis.

Defined as the primary outcome was death associated with SCC. Among the data collected were baseline demographic features, exposure to ultraviolet light, Charlson comorbidity index, smoking status and environmental exposures. For the study, follow-up began at the time of incident SCC diagnosis and ended at death or last recorded date in the health system. 

With 11 patients dying from complications of SCC, including eight in the exposed group and three in the unexposed group, the estimated five- and 10-year cumulative mortality values were 2.9% and 2.9% in the exposed group and 0.4% and 0.9% in the unexposed group, respectively. The study calculated the unadjusted and adjusted cause-specific HRs for SCC mortality associated with exposure as 7.0 (95% CI, 1.8-28.0; P = .006) and 8.0 (95% CI, 2.0-32.8; P = .004), respectively.

“Although the cause-specific mortality is relatively low, patients with IBD exposed to thiopurines who develop SCC have an increased risk of SCC-associated death compared to patients exposed to only mesalamine,” the study authors concluded.

1. Khan N, Lee H, Trivedi C, Kavani H, Medvedeva E, Xie D, Lewis JD, Yang YX. Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Disease Receiving Treatment With Thiopurines. Clin Gastroenterol Hepatol. 2019 Mar 7. pii: S1542-3565(19)30254-X. doi: 10.1016/j.cgh.2019.03.005. [Epub ahead of print] PubMed PMID: 30853615.



Related Articles

Virtual Reality Tested for Phantom Limb Pain in Veteran Amputees

SAN DIEGO—Virtual reality appears to be a feasible way to treat phantom limb pain at the VA, according to a small new study. The report in Pain Medicine sought To describe the development of a... View Article

VA Researcher Helps Develop Promising New Pain Drug

NEW ORLEANS—A new drug with less risk for addiction and overdose compared to currently available opioid medications is showing promise, according to a recently published research article. The drug, developed at Southeast Louisiana Veterans Health... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

Oncology

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article

Oncology

Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article

Oncology

Response of Veterans to PD-1 Checkpoint Inhibitors

RENO, NV—The clinical outcomes and the incidence of adverse events for programmed death-1 checkpoint inhibitors in cancer patients at a VA clinic were different from the data that have been published, according to a new... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up